NCC Group Appoints New Global Capability Leader for Managed Services to Drive Next Chapter of Strategy

NCC Group – one of the world’s largest and most respected security consultancies with over 35 global offices, 2,000 employees and 14,000 clients – today appointed Doug Klotnia as global capability leader for Managed Services.

Life sciences lab automation provider Automata expands into the United States

Automata, a leader in open, integrated laboratory automation, announces its expansion into the US. Automata is accelerating scientific and health outcomes by making automation a reality for every lab.

Thermo Fisher Scientific Simplifies Trace Elemental Analysis in Environmental, Food, Pharmaceutical and Industrial Testing Labs

Today, Thermo Fisher Scientific launched an easy-to-use solution for the analysis of trace elements in environmental, food, and pharmaceutical laboratories. The Thermo Scientific iCAP RQplus ICP-MS Analyzer provides the operational simplicity and stability that laboratories require for ongoing daily analysis of trace elements at low concentrations in a wide range of sample types. The company also announced the Thermo Scientific iSC-65 Autosampler which enhances the productivity of the Thermo Scientific iCAP Qnova Series ICP-MS analyzer and the Thermo Scientific iCAP PRO Series ICP-OES.

New Micropep Executive Appointment Signals Drive to AgTech Product Commercialization

Micropep Technologies appoints Alexandre Frateschi as chief business officer, signaling drive to agTech product commercialization.

Thermo Fisher Scientific Introduces New Low-Flow HPLC Columns for Proteomic Research

PRODUCT BRIEF – March 7, 2023 Thermo Fisher Scientific Introduces New Low-Flow HPLC Columns for Proteomic Research Thermo Scientific µPAC Neo HPLC Columns Deliver Improved Separation Performance and Stability for Biologically Complex Samples News: Thermo Fisher Scientific is providing proteomics and biopharmaceutical research laboratories with a new line of low-flow HPLC columns that improve separation performance and stability of biologically complex samples. Overview: Using a unique micro-pillar separation structure, the Thermo Scientific µPAC Neo HPLC Columns enable researchers to investigate proteomics samples in greater detail, from accurate identification of peptides to determination of protein quantities, discovery of disease biomarkers and post-translational modifications. The newest addition to the portfolio is the µPAC Neo low-load trapping column which is ideally suited for the smallest samples sizes in single-cell proteomics separations and features built-in nanoViper connections to the Vanquish Neo UHPLC systems for ease of use and reduced risk of errors. Users of all µPAC Neo columns benefit from excellent column reproducibility, allowing for more reliable data interpretation and confidence in their results. The full µPAC Neo column portfolio offers: • 50 cm µPAC Neo column for routine proteomics • 110 cm µPAC Neo column for comprehensive proteomics • 50 cm µPAC Neo low-load column for single-cell proteomics • µPAC Neo low-load trapping column to support single-cell proteomics separations µPAC Neo columns are manufactured by micromachined etching of silicon wafers, resulting in highly reproducible separation paths. For proteomics researchers, this provides higher column-to-column consistency and longer column lifetimes compared to packed-bed columns, allowing for more robust development and validation of methods and easier study of larger sample batches. Key Applications: Proteomics and biopharmaceutical research Features/Benefits: • Unique column technology that delivers optimal sample coverage and improved protein identification • Extra-high resolution separations of highest complexity samples • Excellent column reproducibility for more reliable data interpretation • Long column lifetimes to reduce the number of column exchanges and increase system uptime Website: To learn more about the new µPAC Neo HPLC Columns, please visit www.thermofisher.com/lowflowHPLCcolumns. About Thermo Fisher Scientific Thermo Fisher Scientific Inc. is the world leader in serving science, with annual revenue over $40 billion. Our Mission is to enable our customers to make the world healthier, cleaner and safer. Whether our customers are accelerating life sciences research, solving complex analytical challenges, increasing productivity in their laboratories, improving patient health through diagnostics or the development and manufacture of life-changing therapies, we are here to support them. Our global team delivers an unrivaled combination of innovative technologies, purchasing convenience and pharmaceutical services through our industry-leading brands, including Thermo Scientific, Applied Biosystems, Invitrogen, Fisher Scientific, Unity Lab Services, Patheon and PPD. For more information, please visit www.thermofisher.com.

Curebase Selected Among Y Combinator’s Top Private Companies of 2023

DCT platform company places in top 6% of private companies; recognized for end-to-end clinical trial execution built on cutting-edge software

CD ComputaBio Introduces AutoDock, a Powerful Molecular Docking Software

OncoDxRx’s PGA — the world-first platform bridging cell-free mRNA expression to therapies

A Pharmacogenomic Breakthrough Translating Personalized Gene Expression to Therapies

PubHive Integrates with Microsoft Azure Active Directory

PubHive customers can now enable users to automatically sign-on to the PubHive Navigator cloud software platform using secure single sign-on technology powered by Microsoft Azure Active Directory

Creative Enzymes Releases Restriction Enzymes for Molecular Biology Research

Alfa Chemistry to Present at the Upcoming ACS Spring 2023 Conference

Alfa Chemistry, a chemical company focused on supplying high-quality chemicals and materials for both academia and the industry, today announced that members of its Senior Management Team are scheduled to participate in the upcoming ACS Spring 2023 Conference in March at Indiana Convention Center, located in 100 S Capitol Ave, Indianapolis, IN 46225.

Alfa Chemistry Announces to Participate in the Upcoming Pittcon Conference & Exposition 2023

The New York-based chemical vendor Alfa Chemistry recently announced its attendance at the upcoming Pittcon Conference & Exposition 2023. This five-day event will take place at Pennsylvania Convention Center from 18th – 22nd March 2023.

Creative Proteomics Enhances Your Project with Cell Surface Proteomics Service

Creative Proteomics Cytokine Boosts Cancer Research with Cancer Cytokines Assay

Pronalyse Announces the Launch of Epitope Mapping Service Utilizing HDX-MS Technology

Cancer Support Community and Equiva Health partner to create new industry standard for digital cancer support

Equiva Health recently announced a partnership with the Cancer Support Community—the largest professionally led non-profit cancer support network—to launch a pilot program in Minnesota to bring a new, digital model of cancer care to communities that lack access. CSC will use Equiva’s health relationship management platform to bring CSC’s services and resources to patients via broadband-enabled tablets. Those who qualify will also be able to apply for the FCC’s Affordable Connectivity Program via Equiva and ISP provider Infiniti Mobile, providing low to no-cost broadband connection to support access to CSC's resources Overall this partnership is an effort to bring digital cancer care and telemedicine services to underserved communities to improve health equity among these populations.

Form Bio Names Linda Murray as Chief Financial Officer

Form Bio, the breakthrough computational life sciences platform, today announced the appointment of Linda Murray as Chief Financial Officer.

Chugai and Biofourmis Enter into New Partnership Focused on Data-Driven Virtual Care for Endometriosis-Related Pain

Chugai and Biofourmis Enter into New Partnership Focused on Data-Driven Virtual Care for Endometriosis-Related Pain

BRIM Biotechnology announces first patient enrollment in pivotal Phase 3 clinical trial of BRM421 for Dry Eye Disease

BRIM Biotechnology Inc. ("BRIM," TPEx 6885), a clinical-stage biotechnology company advancing novel regenerative therapies to help combat and cure ophthalmology and degenerative joint diseases, announced today that the first patient has been enrolled in its Phase 3 clinical trial of BRM421 for the treatment of Dry Eye Disease (DED).

CD Formulation Upgrades Its Database of Pharmaceutical Excipients, Cosmetic Ingredients, and Food Ingredients